AAT-AD/PD 2018: An Update on Scientific Advances and Clinical Strategies in Alzheimer’s Disease
The AAT-AD/PDTM Focus Meeting 2018 was held in Turin, Italy, March 15-18, 2018. During the new joint meeting between the International Geneva/Springfield Symposium on Advances in Alzheimer Therapy (AAT) and AD/PD,TM the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development, and clinical trials in Alzheimer's, Parkinson's, and other related neurological disorders were at the forefront of the meeting. In this activity, 2 experts summarize the key learnings from this year’s conference focusing on AD.
This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with Alzheimer’s disease or other dementias across the disease continuum.
Upon completion of this activity, participants will be better able to do the following:
- Identify therapies in development for the treatment of AD
- Analyze advances in the development of biomarkers to diagnose AD and to evaluate and monitor interventions
Jeffrey L. Cummings, MD, ScD
Lawrence S. Honig, MD, PhD, FAAN
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Faculty or Presenter||Relationship Identified With:|
|Jeffrey L. Cummings, MD, ScD|
Consultant/Advisor: ACADIA Pharmaceuticals Inc, Accera, Inc, Actinogen Medical, Adamas Pharmaceuticals, Inc, Alkahest, Inc, Allergan plc, Alzheon, Inc, Avanir Pharmaceuticals, Inc, Axovant Sciences Ltd, Axsome Therapeutics, Inc, Bioasis Technologies, Inc., Biogen, Boehringer Ingelheim GmbH, Bracket, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech, Inc, Grifols, Kyowa Kirin International plc., Lundbeck LLC, Medavante Inc, Merck & Co., Inc., Neurocog, NUTRICIA, Otsuka America Pharmaceutical, Inc, QR Pharma, Inc, Resverlogix Corp., Servier, Suven Life Sciences Limited, Takeda Pharmaceutical Company Limited, Toyoma, United Neuroscience, Inc
Stock Ownership: Adamas Pharmaceuticals, Inc, Alzheon, Inc, Bioasis Technologies, Inc., EIP Pharma, LLC, Prana Biotechnology Limited, Sonexa Therapeutics
Royalties/Patents: Copyright ownership of the Neuropsychiatric Inventory (NPI)
Research Grant: Avid Radiopharmaceuticals, Teva Pharmaceutical Industries Ltd.
Lawrence S. Honig, MD, PhD, FAAN
Consultant/Advisor: Bristol-Myers Squibb Company, Eisai Co., Ltd, Eli Lilly and CompanyGrant/Research Support: AbbVie Inc., AstraZeneca, Biogen, Bristol-Myers Squibb Company, Eisai Co., Ltd, Eli Lilly and Company, F. Hoffman-La Roche Ltd, FORUM Pharmaceuticals Inc., Genentech, Inc., Lundbeck LLC, Merck & Co., Inc., TauRx
Non-faculty: Lyerka Miller, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by independent educational grants from Avanir Pharmaceuticals and Biogen.
Jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Miller Medical Communications, LLC, Avanir Pharmaceuticals and Biogen do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician